Champions Oncology (NASDAQ:CSBR) Announces Quarterly Earnings Results

Champions Oncology (NASDAQ:CSBR) issued its quarterly earnings data on Thursday. The biotechnology company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.06, FiscalAI reports. The business had revenue of $15.23 million for the quarter, compared to analysts’ expectations of $15.04 million. Champions Oncology had a negative return on equity of 27.48% and a negative net margin of 1.87%.

Here are the key takeaways from Champions Oncology’s conference call:

• Revenue and profitability improved: First-quarter revenue rose 9% year over year to $15.2 million, gross margin increased to 50% from 43%, and adjusted EBITDA reached $671,000 versus $59,000 a year ago—marking the fifth consecutive quarter of positive adjusted EBITDA.
• Translational oncology services revenue was $14.3 million, with margins benefiting from lower third-party radiolabeling costs after bringing capabilities in-house and from operating leverage.
• Data licensing momentum accelerated: Data revenue reached $893,000, exceeding the total generated in all of fiscal 2026, supported by a broader customer base and a robust pipeline. Management cautioned that licensing revenue will remain lumpy because contracts close on varying timelines.
• Management remains encouraged by discussions with venture groups and potential pharmaceutical partners regarding Corellia AI, but provided no timing for outside funding or a licensing deal. Any such proceeds could be redirected toward data initiatives, other growth projects, and the bottom line.
• The company used approximately $500,000 of cash during the quarter and ended with $4.4 million of cash and no debt. Sales and marketing expenses rose to $3.0 million from $1.8 million as Champions works to generate returns from its expanded commercial organization.

Champions Oncology Price Performance

Shares of NASDAQ:CSBR opened at $5.10 on Friday. The company has a market capitalization of $70.99 million, a PE ratio of -63.75 and a beta of 0.40. The business has a fifty day moving average price of $5.42 and a two-hundred day moving average price of $5.81. Champions Oncology has a 1 year low of $4.83 and a 1 year high of $8.74.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded shares of Champions Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Champions Oncology

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. grew its position in shares of Champions Oncology by 1.9% during the 3rd quarter. Vanguard Group Inc. now owns 333,258 shares of the biotechnology company’s stock valued at $2,158,000 after acquiring an additional 6,229 shares during the period. Acadian Asset Management LLC raised its holdings in shares of Champions Oncology by 28.7% in the 1st quarter. Acadian Asset Management LLC now owns 39,511 shares of the biotechnology company’s stock worth $341,000 after purchasing an additional 8,814 shares during the period. XTX Topco Ltd bought a new stake in shares of Champions Oncology in the 2nd quarter worth approximately $103,000. Essex Investment Management Co. LLC purchased a new position in Champions Oncology in the fourth quarter valued at approximately $126,000. Finally, Jane Street Group LLC purchased a new position in Champions Oncology in the first quarter valued at approximately $200,000. 41.30% of the stock is owned by hedge funds and other institutional investors.

Champions Oncology Company Profile

Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients.